Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2008-02-10 Regulatory Filings
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Progression of Phosphagenics and Nestle`s Phospha E Trial 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 11 February 2008 regarding the progression of a clinical trial and a commercialisation agreement between Phosphagenics Limited and Nestlé Nutrition. It discusses the status of a phase 2 human clinical trial, pre-clinical studies, and business collaboration terms. There are no financial statements, earnings data, or detailed financial analysis present. The content is primarily an update on a clinical trial and business development, typical of a company press release or announcement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. The document is a general company announcement about business progress and partnership, which aligns best with the Regulatory Filings (RNS) category as a general announcement that does not fit other specific categories.
2008-02-10 English
Pre-clinical study results - APA-01 and atorvastatin 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 30 January 2008 reporting pre-clinical study results of a pharmaceutical product combination (APA-01 and atorvastatin). It details study design, results on serum lipids, inflammation biomarkers, and atherosclerotic plaque progression. The content is scientific and promotional in nature, focusing on research findings rather than financial data or regulatory filings. There is no indication of financial statements, management discussion, regulatory compliance, or shareholder meeting materials. The document is a press release announcing research results, not a financial report or regulatory filing. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The closest fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories, but since it is a company announcement of research results, it is best classified as Regulatory Filings (RNS). Confidence is high due to clear content and format.
2008-01-29 English
Successful transdermal oxycodone clinical trial results 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 17 December 2007 from Phosphagenics Limited. It reports positive results from a Phase 1 clinical trial of a transdermal oxycodone delivery technology. The content focuses on clinical trial results, safety, pharmacokinetics, and future development plans. There are no financial statements, regulatory certifications, or detailed financial performance data. The document is a press release announcing clinical trial results rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement of scientific/clinical progress relevant to investors and the market. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2007-12-16 English
Change of Director`s Interest Notice - Mr H Rosen 4 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y - Change of Director’s Interest Notice' and details changes in the shareholding interests of a company director, Mr. Harry Rosen. It references ASX listing rules and provides specific information about the director's securities holdings, acquisitions, and entitlements. The document is a formal notification of a director's personal share transactions, including on-market purchases. There is no indication of financial results, management discussion, or other report types. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length and content confirm it is not a brief announcement or a report publication notice but a full notice of director's interest change.
2007-12-09 English
POH presentation - BBY Healthcare Life Sciences Conference 26 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a presentation given by Dr. Esra Ogru, Executive Vice President of Research & Development, at the BBY 2007 Healthcare & Life Sciences Conference. It contains detailed information about the company's technology, market opportunities, clinical development, management, financial highlights, and future outlook. The document is structured as a slide presentation with multiple sections and graphics, typical of an investor or industry conference presentation. There is no indication that this is an official regulatory filing, annual or interim report, earnings release, or other formal financial document. The presence of forward-looking statements, detailed product pipeline, and strategic information aligns with an investor presentation. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (13,591 characters) supports that this is a full presentation rather than a brief announcement or summary.
2007-12-03 English
December 2007 Newsletter and Annual Report Retention Notice 9 pages ?Kb
Annual Report Classification · 85% confidence The document is a December 2007 newsletter from Phosphagenics Limited, including detailed updates on research and development activities, clinical trials, new appointments, and scientific progress. It is described as a "Newsletter & Annual Report Retention Notice" but the content is primarily a newsletter with R&D updates, clinical trial progress, and company news rather than a formal annual report. The document is about 15,000 characters long, which is substantial but the content is more narrative and update-focused rather than a full financial report. There is no detailed financial performance data or comprehensive financial statements typical of an Annual Report (10-K). The document is not a brief announcement or a regulatory filing, nor is it a presentation or earnings release. It is a company newsletter providing detailed operational and R&D updates to shareholders and the market. Therefore, the best fitting category is Annual Report (10-K) is not appropriate because this is not a full annual report but a newsletter with some annual report retention notice. The newsletter itself is not AGM materials, call transcript, or other categories. Given the content and length, the closest appropriate classification is Annual Report (10-K) because it is an annual communication with detailed company updates, including R&D and clinical trial progress, which is typical of an annual report narrative section, even though it is called a newsletter. The presence of an "Annual Report Retention Notice" suggests it is linked to the annual report cycle. Confidence is high due to the detailed company-wide update and length. FY 2007
2007-12-02 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.